share_log

HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $52

Benzinga ·  Nov 20, 2023 06:22

HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and lowers the price target from $58 to $52.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment